Case study: An antibody-drug conjugate targeting MUC16 for ovarian cancer

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications

Volumn , Issue , 2013, Pages 221-239

  Leipold, Douglas ^a   Mallet, William G ^b  

^a GENENTECH INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84918784455     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5456-4_13     Document Type: Chapter

References (57)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70
2. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14(3): 154-169
3. Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13(3):235-244
4. Teicher BA (2009) Antibody-drug conjugate targets. Curr Cancer Drug Targets 9(8):982-1004
5. Greenbaum D, Colangelo C, Williams K et al (2003) Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 4(9):117
6. Bast RC Jr, Feeney M, Lazarua H et al (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331-1337
7. Høgdall EVS, Christensen L, Kjaer SK et al (2007) CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. Gynecol Oncol 104(3):508-515
8. Kabawat SE, Bast RC, Welch WR et al (1983) Immunopathologic characterization of a monoclo- nal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 79:98-104
9. Rosen DG, Wang L, Atkinson JN et al (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-277
10. Dekker J, Rossen JWA, Buller HA et al (2002) The MUC family: an obituary. Trends Biochem Sci 27(3):126-131
11. O'Brien TJ, Beard JB, Underwood LJ et al (2002) The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumor Biol 23:154-169
12. Yin BWT, Lloyd KO (2001) Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276:27371-27375
13. Yin BWT, Dnistrian A, Lloyd KO (2002) Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 98:737-740
14. Hunter VJ, Weinberg JB, Haney AF et al (1990) CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol 36(2):161-165
15. Macdonald F, Downing R, Allum WH (1988) Expression of CA125 in pancreatic carcinoma and chronic pancreatitis. Br J Cancer 58(4):505-506
16. Belisle JA, Gubbels JAA, Raphael CA et al (2007) Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122(3):418-429
17. Belisle JA, Horibata S, Gubbels JAA et al (2010) Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 9(1):118
18. Gubbels JAA, Belisle J, Onda M et al (2006) Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5(1):50
19. Gubbels JA, Felder M, Horibata S et al (2010) MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer 9(1):11
20. Patankar M, Jing Y, Morrison J et al (2005) Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol 99(3):704-713
21. Rump A, Morikawa Y, Tanaka M et al (2004) Binding of ovarian cancer antigen CA125/ MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279(10):9190-9198
22. Berek JS, Taylor PT, Gordon A et al (2004) Randomized, placebo-controlled study of oregov- omab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22:3507-3516
23. Berek J, Taylor P, McGuire W, Smith L, Schultes B, Nicodemus C (2009) Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27:418-425
24. Ehlen TG, Hoskins PJ, Miller D et al (2005) A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 15(6):1023-1034
25. Schultes BC, Baum RP, Niesen A et al (1998) Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother 46(4):201-212
26. Reinartz S, Kohler S, Schlebusch H et al (2004) Vaccina- tion of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10:1580-1587
27. Sabbatini P, Dupont J, Aghajanian C et al (2006) Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 12(18): 5503-5510
28. Oei AL, Sweep FC, Thomas CMG et al (2008) The use of monoclonal antibodies for the treatment of epithelial ovarian cancer. Int J Oncol 32:1145-1157
29. Argüeso P, Spurr-Michaud S, Russo CL, Tisdale A, Gipson IK (2003) MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest Ophthalmol Vis Sci 44:2487-2495
30. Nouwen EJ, Pollet DE, Eerdekens MW et al (1986) Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen, and cancer antigen 125 in normal and neoplastic human lung. Cancer Res 46(2):866-876
31. Nouwen EJ, Hendrix PG, Dauwe S, Eerdekens MW, De Broe ME (1987) Tumor markers in the human ovary and its neoplasms. A comparative immunohistochemical study. Am J Pathol 126:230-242
32. Nouwen EJ, Dauwe S, De Broe ME (1990) Occurrence of the mucinous differentiation antigen CA125 in genital tract and conductive airway epithelia of diverse mammalian species (rabbit, dog, monkey). Differentiation 45:192-198
33. Chen Y, Clark S, Wong T et al (2007) Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res 67(10):4924-4932
34. Polson AG, Calemine-Fenaux J, Chan P et al (2009) Antibody-drug conjugates for the treatment of non-hodgkin's lymphoma: target and linker-drug selection. Cancer Res 69(6):2358-2364
35. Maeda T, Inoue M, Koshiba S et al (2004) Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem 279: 13174-13182
36. Hamilton TC, Young RC, McKoy WM et al (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43(11):5379-5389
37. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, Mcdonald A, Hayward IP, Schol DJ, Leonard RCF, Smyth JF (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48:6166-6172
38. Junutula JR, Raab H, Clark S et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26(8):925-932
39. Doronina SO, Mendelsohn BA, Bovee TD et al (2006) Enhanced activity of monomethylau- ristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17(1):114-124
40. McGuire WP, Markman M (2003) Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 89:S3-S8
41. Smith JA, Ngo H, Martin MC, Wolf JK (2005) An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol 98(1):141-145
42. Doronina SO, Toki BE, Torgov MY et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21(7):778-784
43. Okeley NM, Miyamoto JB, Zhang X et al (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16(3):888-897
44. Pastuskovas CV, Mallet W, Clark S et al (2010) Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125. Drug Metab Dispos 38(12):2309-2319
45. Hassan R, Remaley AT, Sampson ML et al (2006) Detection and quantitation of serum meso- thelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12(2):447-453
46. Mehta RR, McDermott JH, Heiken TJ, Marler KC, Patel MK, Wild LD et al (1998) Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 16:2409-2416
47. Bast RC Jr, Klug TL, StJohn E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Żurawski VR Jr, Knapp RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887
48. Alley SC, Zhang X, Okeley NM et al (2009) The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 330(3):932-938
49. Alley SC, Benjamin DR, Jeffrey SC et al (2008) Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19(3):759-765
50. Dosio F, Brusa P, Cattel L (2011) immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins 3(7):848-883
51. Thorpe PE, Wallace PM, Knowles PP et al (1987) New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res 47(22):5924-5931
52. Francisco JA (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102(4):1458-1465
53. Sanderson RJ, Hering MA, James SF et al (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 11(2 Pt 1):843-852
54. Mirsalis JC, Schindler-Horvat J, Hill JR et al (1999) Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother Pharmacol 44(5):395-402
55. Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812-1821
56. Frierson HF, Jr et al (2003) Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Human Pathology 34:605-609
57. Frederick PJ, Straughn JM, Jr, Alvarez RD et al (2009) Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecologic Oncology 113:384-390